论文部分内容阅读
浅表膀胱癌经电切大多可治愈。但当存在高期,高级,多发肿瘤,大肿瘤,膀胱原位癌以及丧失ABO(H)抗原,出现异倍体或标记染色体时,肿瘤易复发。这时就用全身或膀胱内化疗但目前尚无一个指标来判断膀胱移行上皮癌是否对化疗敏感。近来研究表明人体内有一个多种药物耐药基因MDR-1,它的编码是一个170000道尔顿的P-糖蛋白——膜转运蛋白(P_(170)),通过能量依赖性的药物泵出的复杂细胞过程,使肿瘤细胞对化疗药物产生耐药作用。但MDR-1在正常尿路上皮及移行上皮癌的表达尚未见报道。作者用核糖核酸酵素及萤光异硫氰酸盐标记的抗P_(170)的单克隆抗体C-219与正常或异常的尿路移行上皮细胞混合,经EPICS 742流式细胞计检
Superficial bladder cancer is mostly curable by electrocution. However, when there are high-grade, advanced, multiple tumors, large tumors, bladder cancer in situ, loss of ABO (H) antigens, and aneuploidy or marker chromosomes, tumors tend to recur. At this time, systemic or intravesical chemotherapy is used but there is currently no indicator to determine whether bladder transitional epithelial cancer is sensitive to chemotherapy. Recent studies have shown that there is a multidrug resistance gene MDR-1 in the human body. It encodes a 170000 dalton P-glycoprotein, a membrane transporter (P 170), which passes an energy-dependent drug pump. The complex cellular processes make tumor cells resistant to chemotherapeutic drugs. However, the expression of MDR-1 in normal urothelial and transitional epithelial carcinoma has not been reported. The authors used ribozyme and fluorescein isothiocyanate-labeled monoclonal antibody C-219 against P 170 to mix with normal or abnormal urinary tract-transplanted epithelial cells and to perform flow cytometry on the EPICS 742.